For decades, one of the central tools used to assess skin involvement in systemic sclerosis has been remarkably simple: a clinician pinches a patient’s skin and judges its thickness by touch. The method remains an accepted part of diagnosis, disease assessment and treatment monitoring, but it is inherently subjective. Two clinicians can score the same patient differently, complicating efforts to determine whether skin fibrosis is worsening, stabilizing or responding to therapy.
Researchers at Boston University Chobanian & Avedisian School of Medicine and the university’s Department of Biomedical Engineering have now tested a camera-based approach intended to add more objective information to that process. The technique, called spatial frequency domain imaging, or SFDI, uses harmless patterned light and measures the way it is reflected by skin. Their work applies the technology to scleroderma for the first time, according to the researchers.
Why measuring skin changes matters
Systemic sclerosis, often called scleroderma, is a rare chronic autoimmune disease. It can prompt the body to produce too much collagen, contributing to thickening and hardening of the skin and, in some cases, internal organs. Skin involvement is therefore not only a visible feature of the disease; it is an important marker clinicians use to understand its extent and progression.
The challenge is that conventional skin scoring depends substantially on an examiner’s tactile judgment. That does not make the assessment unhelpful, but it can limit precision when changes are subtle or when results need to be compared over time and across care teams. A noncontact measurement that can be repeated consistently could give clinicians a second source of evidence alongside physical examination and other tests.
SFDI is designed to do that without a biopsy or direct contact. The system projects patterns of light onto the skin and analyzes the returning light. Those optical measurements can reveal differences in tissue properties that are not readily apparent from a standard visual inspection.
What the researchers found
In their study, the Boston University team reported that light measurements differed between people with scleroderma and healthy individuals. The measurements also tracked with the thickness and fibrosis, or scarring, of the skin.
The group compared the imaging results with collagen buildup observed in skin biopsies, linking the optical signal to the biological change the technique is intended to detect. They also compared the readings with ultrasound measurements of skin thickness and with the standard clinical skin score. In addition, the researchers assessed how repeatable the measurements were.
One particularly notable observation was that readings differed in skin that clinicians had scored as normal. That finding does not establish that every such difference represents clinically important disease. It does, however, suggest that the imaging approach may be sensitive to skin changes that are not obvious during a routine examination.
That possibility is significant in a disease where detecting a shift early could improve the ability to follow an individual patient’s course. The study points to SFDI as a potential complement to existing assessment methods, rather than a replacement for clinical expertise or the established measures already used in care and research.
From research instrument to clinical tool
SFDI has been under development in the laboratory of co-author Darren Roblyer for nearly 15 years. Applying it to scleroderma required testing whether the optical readings could be connected to meaningful features of the disease, including collagen accumulation and skin thickening. The reported comparisons with biopsy findings, ultrasound and clinical scores are important steps toward that validation.
The technology’s noninvasive nature could also be useful for repeated monitoring. Skin biopsies can provide direct tissue information, but they are invasive and cannot be performed casually or frequently. A camera-based measurement could in principle be collected during regular visits, enabling a more continuous record of skin properties.
Still, the findings should be viewed as an early clinical application of an imaging method, not as proof that routine scleroderma assessments are ready to change. The source material describes a developed and tested technique, but does not establish broad clinical deployment, regulatory approval or improved patient outcomes. Larger studies and practical testing in varied care settings would be needed to determine how the measurements should be interpreted and whether they affect treatment decisions.
A bid for more consistent monitoring
The value of the research is its effort to turn an assessment that relies heavily on touch into one that can also be quantified. If further validated, SFDI could help reduce differences between observers and provide clinicians with an additional way to document small changes over time.
For people living with systemic sclerosis, the practical promise is not simply a new camera. It is the prospect of more consistent measurement of a complex disease process. The work also illustrates how optical engineering can be adapted for clinical questions that have resisted easy quantification. By examining how light interacts with fibrotic skin, researchers may have opened a path toward assessing disease activity with less discomfort and greater repeatability.
- SFDI uses patterned, harmless light to measure skin properties without contact.
- The study found differences between people with scleroderma and healthy participants.
- Researchers compared optical readings with biopsies, ultrasound and standard clinical scoring.
- Further research is needed before the method can be considered a routine clinical tool.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
